Multiple Sclerosis Market in US to Grow by USD 4.99 Billion from 2025-2029, Driven by a Strong Vendor Pipeline and AI-Powered Market Evolution - Technavio

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The multiple sclerosis market in us size is estimated to grow by USD 4.99 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  6.2%  during the forecast period. Strong pipeline of vendors is driving market growth, with a trend towards rising strategic alliances and partnerships among vendors. However, high cost of drugs  poses a challenge. Key market players include AB Science SA, Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., GeNeuro SA, Glenmark Pharmaceuticals Ltd., Inno BioScience LLC, Johnson and Johnson Inc., Mapi Pharma Ltd., MediciNova Inc., Merck KGaA, Novartis AG, Opexa Therapeutics Inc., Pfizer Inc., Sanofi SA, Sobel Network Shipping Co. Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Multiple Sclerosis (MS) is a debilitating immune-mediated disease affecting over 2.3 million people worldwide. The market for MS therapeutics continues to grow, driven by the need for effective treatments and advancements in technology. Side effects from injectable drugs remain a concern, leading to the development of biosimilars and oral alternatives. Neurotherapy treatments, such as voice commands and assistive robotic arms, are improving patient care and accessibility. Efficacy and safety are key considerations in the development of new MS drugs, including immunostimulants and novel molecules. Ocrevus, a humanized monoclonal antibody, has shown promise in phase 3 clinical studies for relapsing-remitting MS. Disease-modifying treatments, such as dimethyl fumarate and glatiramer acetate, are commonly used to manage MS symptoms and slow disease progression. Healthcare spending on MS treatments is increasing, driven by the high cost of injectable drugs and the need for long-term care. Research and development of new treatments, including immunosuppressive drugs and monoclonal antibodies, is ongoing. The MS treatment algorithm continues to evolve, with a focus on early intervention and personalized care. Diagnosis and care for MS patients require a multidisciplinary approach, involving hospital pharmacists, physical therapy, and healthcare resources. Spinal cord damage from demyelination and neuroaxonal loss can lead to disabilities, making accessibility and affordability of treatments crucial. Technological developments, such as tDCS and infused medications, offer new possibilities for MS treatment. The market for MS treatments is expected to continue growing, driven by the need for effective and accessible care for this population. 

Vendors in the Multiple Sclerosis market are strengthening their positions by forming strategic partnerships and acquisitions to broaden their treatment offerings. For instance, in September 2024, Roche obtained FDA approval for an injectable version of its successful MS treatment, Ocrevus. These collaborations enable companies to combine expertise, resources, and accelerate innovation in therapeutic solutions. Such alliances are essential for creating holistic treatment approaches addressing both medical and psychosocial patient needs. By sharing knowledge and technology, vendors can expedite new therapy introductions and enhance existing ones, driving market growth throughout the forecast period. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

•         Multiple Sclerosis (MS) is an immune-mediated disease affecting over 2.3 million people worldwide. The disease's pathogenesis involves demyelination and neuroaxonal loss, leading to disabilities. MS treatments include injectable drugs like interferons, glatiramer acetate, and humanized monoclonal antibodies such as natalizumab, ocrelizumab, and alemtuzumab. Immunostimulants like dimethyl fumarate and teriflunomide are oral options. Side effects and accessibility are significant challenges. Technological developments like voice commands and assistive robotic arms enhance care. Biosimilars and generics offer cost savings, but maintaining efficacy is crucial. Advancements include neurotherapy treatments, immunosuppressive drugs, and tDCS. Healthcare resources are strained due to increasing patient volumes and healthcare spending. Phase 3 clinical studies explore novel molecules, treatment algorithms, and disease progression. Diagnosis and treatment remain complex, requiring specialized healthcare expertise. MS drugs include injectable, infused, and oral medications. Spinal cord injuries and degenerative changes are common complications. MS care includes physical therapy, muscle relaxants, and symptom management. Healthcare expenditure is high due to the chronic nature of the disease and the need for ongoing treatment. The disease affects relapsing-remitting, primary-progressive, and secondary-progressive forms. Despite these challenges, research and development continue, with product launches and phase 3 trials offering hope for improved treatments and care.

•         Multiple Sclerosis (MS) is a debilitating autoimmune disease characterized by the immune system attacking the protective myelin sheath surrounding nerve fibers in the central nervous system. Symptoms vary greatly and may include vision loss, pain, fatigue, and impaired coordination. MS impacts communication between the brain and the body, leading to significant challenges. Despite available treatments that can help manage symptoms, modify disease progression, and facilitate recovery, the lifetime cost per MS patient exceeds USD4 million. This highlights the substantial economic burden of MS on individuals and healthcare systems.

Discover how AI is revolutionizing market trends- Get your access now!

This multiple sclerosis market in US report extensively covers market segmentation by  

1. Route Of Administration 
• 1.1 Parenteral
• 1.2 Oral
2. Type 
• 2.1 Biologics
• 2.2 Small molecules
3. Geography 
• 3.1 North America

1.1 Parenteral- 

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Multiple Sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to various symptoms such as muscle weakness, balance and coordination problems, vision loss, and cognitive impairment. The prevalence of MS is increasing globally, making it a significant healthcare concern. Clinical trials are ongoing to develop new medications and immunostimulant therapies to manage MS progression and improve patient outcomes. Healthcare innovation includes voice-controlled healthcare devices and robotic arm rehabilitation to enhance patient care. Generic medications are playing a crucial role in MS management through drug accessibility initiatives and cost containment. Neurological research focuses on biomarkers, clinical data, and medical advancements to understand MS better and improve clinical outcomes. The use of immune system modulation drugs and biotechnology in MS treatment is a promising area of medical research. Public health initiatives aim to improve the quality of life of MS patients by addressing healthcare cost containment and ensuring the availability of MS drugs and medical devices. The goal is to provide optimal MS care through a combination of medical research, healthcare technology, and patient-centered approaches.

Multiple Sclerosis (MS) is an immune-mediated disease characterized by demyelination and neuroaxonal loss, leading to debilitating disabilities. The disease affects over 2.5 million people worldwide, with prevalence varying by population and healthcare resources. MS therapeutics aim to modify the immune response, reduce relapses, manage symptoms, and prevent disease progression. Injectable drugs, such as interferons, glatiramer acetate, and monoclonal antibodies (natalizumab, ocrelizumab, and alemtuzumab), are common treatments. Novel molecules, like dimethyl fumarate and teriflunomide, offer oral alternatives. Immunostimulants, like amantadine, and immunosuppressive drugs are also used. Advancements include technological developments like voice commands and assistive robotic arms, neurotherapy treatments, and biosimilars. Phase 3 clinical studies explore the efficacy of new treatments, while generics and product launches increase accessibility. Healthcare spending on MS treatments is significant, with hospital pharmacies playing a crucial role in managing patient volumes and ensuring proper care. The disease's complex pathogenesis requires ongoing research and development to improve treatment algorithms and address degenerative changes in the brain and spinal cord, including axonal transection and muscle relaxants for nerve cells. MS is a relapsing-remitting and progressive disease, with primary-progressive and secondary-progressive forms. Treatment goals include managing symptoms, improving accessibility, and reducing healthcare expenditure. Injections, infused medications, and physical therapy are essential components of MS care.

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Route Of Administration
• Parenteral
• Oral
• Type
• Biologics
• Small Molecules
• Geography
• North America

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio